Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy NeoGenomics stock

Learn how to easily invest in NeoGenomics stock.

NeoGenomics Inc is a diagnostics & research business based in the US. NeoGenomics shares (NEO) are listed on the NASDAQ and all prices are listed in US Dollars. NeoGenomics employs 1,700 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in NeoGenomics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NEO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

NeoGenomics stock price (NASDAQ: NEO)

Use our graph to track the performance of NEO stocks over time.

NeoGenomics shares at a glance

Information last updated 2022-01-16.
Latest market close$24.94
52-week range$24.03 - $61.57
50-day moving average $34.53
200-day moving average $42.49
Wall St. target price$48.82
PE ratio 61.8859
Dividend yield N/A (0%)
Earnings per share (TTM) $0.40

Buy NeoGenomics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
SoFi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
Get a free stock valued up to $3500
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
$125 - $625
Open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy NeoGenomics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NeoGenomics price performance over time

Historical closes compared with the close of $24.94 from 2022-01-14

1 week (2022-01-11) -11.09%
1 month (2021-12-17) -26.88%
3 months (2021-10-18) -42.86%
6 months (2021-07-16) -42.49%
1 year (2021-01-15) -52.75%
2 years (2020-01-17) -22.18%
3 years (2019-01-18) 57.65%
5 years (2017-01-18) 196.55%

Is NeoGenomics stock undervalued or overvalued?

Valuing NeoGenomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NeoGenomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

NeoGenomics's P/E ratio

NeoGenomics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 62x. In other words, NeoGenomics shares trade at around 62x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

NeoGenomics's PEG ratio

NeoGenomics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.02. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NeoGenomics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

NeoGenomics's EBITDA

NeoGenomics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $30 million.

The EBITDA is a measure of a NeoGenomics's overall financial performance and is widely used to measure a its profitability.

NeoGenomics financials

Revenue TTM $484.6 million
Gross profit TTM $186.4 million
Return on assets TTM -2.19%
Return on equity TTM 5.42%
Profit margin 10.08%
Book value $9.23
Market capitalisation $3.1 billion

TTM: trailing 12 months

NeoGenomics share dividends

We're not expecting NeoGenomics to pay a dividend over the next 12 months.

Have NeoGenomics's shares ever split?

NeoGenomics's shares were split on a 1:100 basis on 15 April 2003. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NeoGenomics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for NeoGenomics shares which in turn could have impacted NeoGenomics's share price.

NeoGenomics share price volatility

Over the last 12 months, NeoGenomics's shares have ranged in value from as little as $24.03 up to $61.57. A popular way to gauge a stock's volatility is its "beta".

NEO.US volatility(beta: 0.63)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeoGenomics's is 0.63. This would suggest that NeoGenomics's shares are less volatile than average (for this exchange).

NeoGenomics overview

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Frequently asked questions

What percentage of NeoGenomics is owned by insiders or institutions?
Currently 4.284% of NeoGenomics shares are held by insiders and 96.038% by institutions.
How many people work for NeoGenomics?
Latest data suggests 1,700 work at NeoGenomics.
When does the fiscal year end for NeoGenomics?
NeoGenomics's fiscal year ends in December.
Where is NeoGenomics based?
NeoGenomics's address is: 12701 Commonwealth Drive, Fort Myers, FL, United States, 33913
What is NeoGenomics's ISIN number?
NeoGenomics's international securities identification number is: US64049M2098
What is NeoGenomics's CUSIP number?
NeoGenomics's Committee on Uniform Securities Identification Procedures number is: 64049M209

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site